Abstract
This study (August-September 2021) estimated the seroprevalence of SARS-CoV-2 neutralizing antibodies in the general population of Delhi and correlated it with their anti-SARS-CoV-2 IgG levels. Samples were selected by simple random sampling method. The neutralizing capacity was estimated by performing a surrogate virus neutralization test (sVNT) (GenScript), Piscataway, NJ, USA. A total of 2233 (87.1%, 95% C.I. 85.7, 88.3) of the 2564 SARS-CoV-2 IgG seropositive samples had detectable SARS-CoV-2 neutralizing antibodies. In samples with S/CO ≥ 4.00, the neutralizing antibodies ranged from 94.5% to 100%. The SARS-CoV-2 neutralizing antibody seroprevalence strongly correlated with the S/CO range of IgG SARS-CoV-2 (r = 0.62, p = 0.002).
Keywords: Anti-SARS-CoV-2 neutralizing antibody; Covid-19; SARS-CoV-2; Vaccination.
【저자키워드】 COVID-19, SARS-CoV-2, vaccination., Anti-SARS-CoV-2 neutralizing antibody, 【초록키워드】 neutralizing antibody, IgG, anti-SARS-CoV-2 IgG, virus neutralization test, Neutralizing, neutralizing capacity, General population, USA, SARS-CoV-2 neutralizing antibodies, SARS-CoV-2 IgG, SARS-CoV-2 neutralizing antibody, sVNT, random, Genscript, selected, Sample, detectable, correlated, ranged, seropositive sample, 【제목키워드】 Antibody Response, Analysis,